Document is current

Article History

Received: 19 May 2022

Accepted: 29 July 2022

First Online: 22 September 2022

Declarations

:

: The study had ethical approval and was registered at the German Clinical Trials Register (DRKS00022024). STROBE guidelines were followed.

: The authors declare the following financial interests or personal relationships that may be considered as potential competing interests: FR reports personal fees from Angelini Pharma/Arvelle Therapeutics, Eisai GmbH, GW Pharmaceuticals/Jazz Pharma, Roche Pharma, and UCB Pharma, and grants from the Detlev-Wrobel-Fonds for Epilepsy Research, the Deutsche Forschungsgemeinschaft (DFG), the Federal Ministry of Education and Research (BMBF), the LOEWE Programme of the State of Hesse, and the European Union. LL reports speakers’ honoraria from Eisai, GW pharmaceuticals, and Biogen. SK reports speakers’ honoraria from Eisai, research funding from Biogen, and grants from the Deutsche Forschungsgemeinschaft (DFG). FvP reports speakers’ honoraria from Bial, Eisai, GW Pharmaceutical, Angelini Pharma, Zogenix, and UCB Pharma, and scientific advisory board honoraria from GW Pharmaceutical companies, UCB Pharma, and Angelini Pharma. CM reports speakers’ honoraria from Eisai and travel support from GW Pharmaceuticals. AS reports personal fees and grants from Angelini Pharma, Desitin Arzneimittel, Eisai, GW Pharmaceuticals, Marinus Pharma, Precisis, UCB, UNEEG medical, and Zogenix. KK, MM, HM, and LMW report no conflicts of interest.